<p>根据 Securities and Exchange Commission 最近的 13F 表格，Saratoga Research &amp; Investment Management 在第二季度将其在罗氏控股公司（OTCMKTS:RHHBY - 免费报告）的持股减少了 2.2%。该公司在此期间出售了 44,075 股后，持有 1,978,134 股罗氏股票。罗氏占 Saratoga Research &amp; Investment Management 投资组合的 4.3%，是其第九大持股。截至其最近的 SEC 备案，Saratoga Research &amp; Investment Management 在罗氏的持股价值为 80,629,000 美元。</p>
<ul>
<li>3 只在美国投资超过 1000 亿美元的大型制药股。</li>
</ul>
<p>其他一些对冲基金最近也调整了对该公司的持股。Rhumbline Advisers 在第一季度将其在罗氏的持股增加了 7.4%。Rhumbline Advisers 现在持有 107,252 股罗氏股票，价值 4,413,000 美元，此前在此期间又购买了 7,374 股。OLD National Bancorp IN 在第二季度将其在罗氏的股份增加了 2.9%。OLD National Bancorp IN 现在持有 261,317 股罗氏股票，价值 10,604,000 美元，此前在此期间又购买了 7,326 股。Enterprise Financial Services Corp 在第二季度购买了罗氏的新头寸，价值约 208,000 美元。FineMark National Bank &amp; Trust 在第二季度购买了罗氏的新头寸，价值约 210,000 美元。最后，North Star Asset Management Inc.在第二季度将其在罗氏的股份增加了 52.0%。North Star Asset Management Inc.现在持有 26,305 股罗氏股票，价值 1,072,000 美元，此前在此期间又收购了 9,000 股。</p>
<h2>分析师设定新目标价</h2>
<p>一些研究公司对 RHHBY 发表了评论。摩根大通在 12 月 8 日的研究报告中将罗氏的股票评级从 “减持” 上调至 “中性”。摩根士丹利在 12 月 2 日的报告中重申了对罗氏股票的 “减持” 评级。Zacks Research 在 12 月 5 日的研究报告中将罗氏的评级从 “持有” 下调至 “强烈卖出”。汇丰银行在周三重申了 “买入” 评级，并对罗氏股票设定了 57.00 美元的目标价。最后，德意志银行在 11 月 11 日的研究报告中将罗氏的评级从 “卖出” 上调至 “持有”。三位分析师给予该股票 “强烈买入” 评级，一位给予 “买入” 评级，两位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat，该股票的平均评级为 “适度买入”，平均目标价为 57.00 美元。</p>
<ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
<p><strong>获取我们关于 RHHBY 的最新股票报告</strong></p>
<h2>罗氏股票表现</h2>
<p>罗氏股票在周五开盘价为 50.04 美元。罗氏控股公司在过去 12 个月的最低价为 34.10 美元，最高价为 50.67 美元。该公司的 50 日移动平均价格为 45.44 美元，200 日移动平均价格为 42.31 美元。</p>
<h2>罗氏简介</h2>
<p>（免费报告）</p>
<ul>
<li>NVIDIA 投资了这两只 AI 股票，你应该投资吗？</li>
</ul>
<p>罗氏控股公司在欧洲、北美、拉丁美洲、亚洲、非洲、澳大利亚和大洋洲从事制药和诊断业务。该公司在贫血、血液和实体肿瘤、皮肤病、血友病、炎症和自身免疫、神经系统疾病、眼科、呼吸系统疾病和移植等治疗领域提供药品。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过罗氏</li>
<li>什么是支撑位？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
<li>大型股的定义及如何投资</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>为什么股票行业对成功投资至关重要？</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在罗氏吗？</h2>
<p>在考虑罗氏之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而罗氏并不在名单上。</p>
<p>虽然罗氏目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

罗氏(ADR)

Saratoga投资

<p>Saratoga 投资管理在第二季度减少了对罗氏 (ADR) 的持股 2.2%，目前持有 1,978,134 股，价值 8063 万美元。罗氏是该公司的第九大持股，占其投资组合的 4.3%。其他对冲基金也调整了在罗氏的头寸。分析师对罗氏的评级褒贬不一，平均评级为 “适度买入”，目标价格为 57.00 美元</p>

<p>Saratoga Research &amp; Investment Management cut its holdings in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 2.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,978,134 shares of the company's stock after selling 44,075 shares during the period. Roche accounts for 4.3% of Saratoga Research &amp; Investment Management's portfolio, making the stock its 9th largest holding. Saratoga Research &amp; Investment Management's holdings in Roche were worth $80,629,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据 Securities and Exchange Commission 最近的 13F 表格，Saratoga Research &amp; Investment Management 在第二季度将其在罗氏控股公司（OTCMKTS:RHHBY - 免费报告）的持股减少了 2.2%。该公司在此期间出售了 44,075 股后，持有 1,978,134 股罗氏股票。罗氏占 Saratoga Research &amp; Investment Management 投资组合的 4.3%，是其第九大持股。截至其最近的 SEC 备案，Saratoga Research &amp; Investment Management 在罗氏的持股价值为 80,629,000 美元。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只在美国投资超过 1000 亿美元的大型制药股。</li>
</ul>
</div><p>A number of other hedge funds have also recently modified their holdings of the business. Rhumbline Advisers raised its holdings in Roche by 7.4% in the 1st quarter. Rhumbline Advisers now owns 107,252 shares of the company's stock worth $4,413,000 after purchasing an additional 7,374 shares during the period. OLD National Bancorp IN raised its stake in shares of Roche by 2.9% in the second quarter. OLD National Bancorp IN now owns 261,317 shares of the company's stock worth $10,604,000 after buying an additional 7,326 shares during the period. Enterprise Financial Services Corp bought a new position in shares of Roche in the second quarter worth about $208,000. FineMark National Bank &amp; Trust purchased a new position in shares of Roche during the 2nd quarter valued at about $210,000. Finally, North Star Asset Management Inc. grew its stake in shares of Roche by 52.0% during the 2nd quarter. North Star Asset Management Inc. now owns 26,305 shares of the company's stock valued at $1,072,000 after acquiring an additional 9,000 shares during the period.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也调整了对该公司的持股。Rhumbline Advisers 在第一季度将其在罗氏的持股增加了 7.4%。Rhumbline Advisers 现在持有 107,252 股罗氏股票，价值 4,413,000 美元，此前在此期间又购买了 7,374 股。OLD National Bancorp IN 在第二季度将其在罗氏的股份增加了 2.9%。OLD National Bancorp IN 现在持有 261,317 股罗氏股票，价值 10,604,000 美元，此前在此期间又购买了 7,326 股。Enterprise Financial Services Corp 在第二季度购买了罗氏的新头寸，价值约 208,000 美元。FineMark National Bank &amp; Trust 在第二季度购买了罗氏的新头寸，价值约 210,000 美元。最后，North Star Asset Management Inc.在第二季度将其在罗氏的股份增加了 52.0%。North Star Asset Management Inc.现在持有 26,305 股罗氏股票，价值 1,072,000 美元，此前在此期间又收购了 9,000 股。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of research firms have commented on RHHBY. JPMorgan Chase &amp; Co. upgraded shares of Roche from an &#34;underweight&#34; rating to a &#34;neutral&#34; rating in a research note on Monday, December 8th. Morgan Stanley reaffirmed an &#34;underweight&#34; rating on shares of Roche in a report on Tuesday, December 2nd. Zacks Research lowered Roche from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Friday, December 5th. HSBC restated a &#34;buy&#34; rating and issued a $57.00 price objective on shares of Roche in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft raised Roche from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Tuesday, November 11th. Three analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $57.00.</p>
<div class="lb-trans"><p>一些研究公司对 RHHBY 发表了评论。摩根大通在 12 月 8 日的研究报告中将罗氏的股票评级从 “减持” 上调至 “中性”。摩根士丹利在 12 月 2 日的报告中重申了对罗氏股票的 “减持” 评级。Zacks Research 在 12 月 5 日的研究报告中将罗氏的评级从 “持有” 下调至 “强烈卖出”。汇丰银行在周三重申了 “买入” 评级，并对罗氏股票设定了 57.00 美元的目标价。最后，德意志银行在 11 月 11 日的研究报告中将罗氏的评级从 “卖出” 上调至 “持有”。三位分析师给予该股票 “强烈买入” 评级，一位给予 “买入” 评级，两位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat，该股票的平均评级为 “适度买入”，平均目标价为 57.00 美元。</p>
</div><ul>
<li>Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics：GLP-1 制造商会在批准前被收购吗？</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on RHHBY</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 RHHBY 的最新股票报告</strong></p>
</div><h2>Roche Stock Performance</h2>
<div class="lb-trans"><h2>罗氏股票表现</h2>
</div><p>Shares of Roche stock opened at $50.04 on Friday. Roche Holding AG has a twelve month low of $34.10 and a twelve month high of $50.67. The business has a 50-day moving average price of $45.44 and a 200-day moving average price of $42.31.</p>
<div class="lb-trans"><p>罗氏股票在周五开盘价为 50.04 美元。罗氏控股公司在过去 12 个月的最低价为 34.10 美元，最高价为 50.67 美元。该公司的 50 日移动平均价格为 45.44 美元，200 日移动平均价格为 42.31 美元。</p>
</div><h2>Roche Profile</h2>
<div class="lb-trans"><h2>罗氏简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><ul>
<li>NVIDIA Invested in These 2 AI Stocks, Should You?</li>
</ul>
<div class="lb-trans"><ul>
<li>NVIDIA 投资了这两只 AI 股票，你应该投资吗？</li>
</ul>
</div><p>Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.</p>
<div class="lb-trans"><p>罗氏控股公司在欧洲、北美、拉丁美洲、亚洲、非洲、澳大利亚和大洋洲从事制药和诊断业务。该公司在贫血、血液和实体肿瘤、皮肤病、血友病、炎症和自身免疫、神经系统疾病、眼科、呼吸系统疾病和移植等治疗领域提供药品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Roche</li>
<li>What is a support level?</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
<li>Large Cap Stock Definition and How to Invest</li>
<li>Why Amazon Could Be a $300 Stock Within Weeks</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过罗氏</li>
<li>什么是支撑位？</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
<li>大型股的定义及如何投资</li>
<li>为什么亚马逊可能在几周内成为 300 美元的股票</li>
<li>为什么股票行业对成功投资至关重要？</li>
<li>Adobe 在财报后获得提振：长期前景看涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU9UQ01LVFMmU3ltYm9sPVJISEJZ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=OTCMKTS&amp;Symbol=RHHBY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Roche Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在罗氏吗？</h2>
</div><p>Before you consider Roche, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑罗氏之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而罗氏并不在名单上。</p>
</div><p>While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然罗氏目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Saratoga Research & Investment Management 在罗氏控股股份公司持有价值 8063 万美元的头寸